Anebulo Pharmaceuticals

ANEB

Market cap $96.5M

Overview Fund Activity

2.35 USD

-0.14

5.62%

At close Updated Sep 17, 11:57 AM EDT

1 day

-5.62%

5 days

13.53%

1 month

-8.91%

3 months

59.86%

6 months

50.64%

Year to date

48.73%

1 year

3.52%

5 years

-66.9%

10 years

-66.9%

About: Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company, developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.

Employees: 2

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

100% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 3

11% more capital invested

Capital invested by funds: $29.4M [Q1] → $32.5M (+$3.13M) [Q2]

0% more funds holding

Funds holding: 18 [Q1] → 18 (+0) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

0.06% less ownership

Funds ownership: 55.05% [Q1] → 54.99% (-0.06%) [Q2]

See Fund Rankings

Financial journalist opinion

Anebulo Pharmaceuticals Announces Update on Going Private Transaction and Strategic Alternatives

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Announces Update on Going Private Transaction and Strategic Alternatives.

Anebulo Pharmaceuticals Announces Update on Going Private Transaction and Strategic Alternatives

Anebulo Pharmaceuticals Approves Plan to Terminate Registration of Its Common Stock

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced that a Special Committee of independent directors has recommended, and its Board of Directors (the “Board”) has approved, as part of a going private transaction, a reverse stock split at a ratio of not less than 1-for-2,500 and not greater than.

Anebulo Pharmaceuticals Approves Plan to Terminate Registration of Its Common Stock

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Updates

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced financial results for the three months ended March 31, 2025, and recent updates. Third Quarter Fiscal Year 2025 and Subsequent Highlights: Anebulo is prioritizing the advancement of an intravenous selonabant as a potential treatment for pediatri.

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Updates

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced financial results for the three months ended December 31, 2024, and recent updates. Second Quarter Fiscal Year 2025 and Subsequent Highlights: In December 2024, Anebulo met with FDA to discuss the development of intravenous selonabant and the in.

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates

Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise.

Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates.

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates.

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates

Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), has been awarded the first tranche of a two year cooperative grant of up to approximately $1.9 million from the National Institute on Drug Abuse (“NIDA”), part of the National Institutes of Health (“NIH”), to support the development of intravenous selonabant.

Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects

Galehead Development to Collaborate With Rivian Automotive on Renewable Energy Project Development

BOSTON--(BUSINESS WIRE)--Galehead Development, LLC (“Galehead”) and Rivian Automotive, LLC (“Rivian”) have entered into an agreement to collaborate on the development of renewable energy resources tailored to Rivian's locational and environmental priorities. Galehead will develop solar projects with specific consideration for Rivian's “3C” Framework. The 3C Framework is a progressive procurement standard that commits Rivian to sourcing renewable energy from projects that have a measurable posit.

Galehead Development to Collaborate With Rivian Automotive on Renewable Energy Project Development

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid toxicities that include acute cannabinoid intoxication (ACI) and unintentional cannabis poisoning (the “Company” or “Anebulo”), today announced financial results for the three months ended March 31, 2024, and recent updates. Third Quarter Fiscal Year 2024 and Subsequent Highlights: Anebulo prioritizes deve.

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates

See News Rankings

Charts implemented using Lightweight Charts™